Developer docs
API playgroundTry for free, no card

Search company profiles

Protalix BioTherapeutics

Full company profile

uuid0003nf3

Namestring
Protalix BioTherapeutics
Legal namestring
Protalix BioTherapeutics Inc.
Websiteurl
protalix.com
Company typeenum
Public
Founded yearint
1994
Descriptiontext

Protalix BioTherapeutics, Inc. is a publicly traded biopharmaceutical company (NYSE American: PLX) founded in 1994 and headquartered in Carmiel, Israel, that develops and manufactures recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression platform. The company has commercialized two FDA-approved enzyme replacement therapies produced via genetically engineered plant cell suspension cultures in disposable polyethylene bioreactors: Elelyso (taliglucerase alfa) for Type 1 Gaucher disease, approved in 2012 as the first plant cell-expressed protein therapeutic approved by the FDA; and Elfabrio (pegunigalsidase alfa) for adult Fabry disease, approved by the FDA in 2023. Protalix's clinical pipeline includes PRX-115, a PEGylated recombinant uricase in Phase 2 for uncontrolled gout, and PRX-119, a PEGylated DNase I in preclinical research for NETs-related diseases.

The company operates a capital-light, partnership-driven commercialization model. All marketed products are sold through strategic channel partners rather than direct sales infrastructure: Pfizer holds global rights to Elelyso (excluding Brazil, where Fiocruz distributes), and Chiesi Global Rare Diseases holds global rights to Elfabrio. Revenue streams consist of product supply/manufacturing payments, royalties, and regulatory and commercial milestone payments from these partners, supplemented by recent milestone income (e.g., a $25M payment from Chiesi in Q1 2026 tied to European Commission approval of Elfabrio's every-four-weeks dosing regimen). FY2026 revenue is guided to $78-83M with $51.1M of cash as of March 31, 2026. End customers are patients with rare genetic lysosomal storage disorders and (in the pipeline) broader populations with gout and NETs-related diseases; the company is actively seeking additional collaborations to expand its pipeline beyond enzyme replacement therapy into oligonucleotide-based therapeutics for rare renal indications through a December 2025 agreement with Secarna Pharmaceuticals.

Short descriptiontext

Protalix BioTherapeutics is an Israel-based, publicly traded biopharmaceutical company that develops and manufactures recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression platform, commercializing FDA-approved enzyme replacement therapies Elelyso (Gaucher disease) and Elfabrio (Fabry disease) via partners Pfizer, Chiesi, and Fiocruz.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCarmiel, Israel
HQ citystring
Carmiel
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant protein production, enzyme replacement therapy, plant cell expression, biopharmaceutical manufacturing, rare disease therapeutics
Industry2 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Elelyso & Elfabrio)
TypeLicensing Royalties
Description

Revenue from product sales to commercialization partners including Pfizer (Elelyso) and Chiesi (Elfabrio), as well as Fiocruz in Brazil. Products are approved in multiple markets including US, EU, Brazil, Israel and others.

protalix.com
2Milestone Payments
TypeLicensing Royalties
Description

One-time regulatory milestone payments triggered by approvals. Q1 2026 included $25 million milestone from Chiesi following European Commission approval of Elfabrio E4W dosing regimen.

prnewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ProCellEx
Description

Proprietary plant cell-based protein expression platform used to produce recombinant therapeutic proteins

protalix.com
+2 more records
Core offering1 text field

Protalix BioTherapeutics develops and manufactures recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company has commercialized two FDA-approved enzyme replacement therapies—Elelyso (taliglucerase alfa) for Type I Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease—through strategic partnerships with Pfizer and Chiesi Global Rare Diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Elfabrio approved in US, EU, Great Britain, Switzerland, Israel
+3 more records
Product overview1 text field

Protalix BioTherapeutics is a biopharmaceutical company that has developed two FDA-approved enzyme replacement therapies: Elelyso for type I Gaucher disease and Elfabrio for Fabry disease, both produced through the proprietary ProCellEx plant cell-based expression platform. The company is advancing its clinical pipeline with PRX-115 (PEGylated uricase for uncontrolled gout in Phase 2) and PRX-119 (PEGylated DNase I for NETs-related diseases in research/preclinical stages).

Product and service5 records
1Elfabrio (pegunigalsidase alfa)
CategoryEnzyme Replacement Therapy (FDA-approved)
Description

Elfabrio is an enzyme replacement therapy (ERT) for adult patients with Fabry disease, replacing the deficient alpha-galactosidase-A enzyme through intravenous infusion. It is expressed in plant cell culture with a covalently bound polyethylene glycol polymer linker, commercialized globally by Chiesi Global Rare Diseases.

2Elelyso (taliglucerase alfa)
CategoryEnzyme Replacement Therapy (FDA-approved)
Description

Elelyso is an enzyme replacement therapy for patients with Type 1 Gaucher disease, replacing the deficient glucocerebrosidase enzyme with a recombinant form of the protein produced through the ProCellEx platform. It was the first plant cell-based recombinant therapeutic protein approved by the FDA, commercialized globally by Pfizer (excluding Brazil) and by Fiocruz in Brazil.

3PRX-115
CategoryPipeline Biologic (Recombinant PEGylated Uricase)
Description

PRX-115 is a recombinant PEGylated uricase enzyme in development for the potential treatment of uncontrolled gout. The uricase enzyme converts uric acid to allantoin, designed to lower uric acid levels with low immunogenicity and increased half-life.

4PRX-119
CategoryPipeline Biologic (PEGylated DNase I)
Description

PRX-119 is a PEGylated Deoxyribonuclease (DNase) I enzyme in development for NETs-related diseases, designed to degrade circulating NETs-related cell-free DNA levels and decrease NET-mediated pathology.

5ProCellEx Plant Cell-Based Protein Expression Platform
CategoryProprietary Manufacturing / Collaboration Platform
Description

ProCellEx is Protalix's proprietary plant cell-based expression platform for producing and manufacturing recombinant therapeutic proteins, offering an alternative to mammalian cell-based production with production, regulatory, and cost benefits. Protalix actively offers the platform for collaborations and co-development of new rare disease therapeutics with high unmet medical need.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Collaboration and option agreement to develop oligonucleotide therapies for rare renal indications. Leverages Protalix's expertise in rare diseases and Secarna's AI platform. Joint research with Protalix obtaining exclusive option to license active compounds for clinical development. Companies aim to advance therapies from preclinical stages through clinical trials and potential commercialization.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-01-01
Description

Chiesi Global Rare Diseases (business unit of Chiesi Group) is the global partner for commercialization of Elfabrio (pegunigalsidase alfa) for Fabry disease. Collaboration began in 2017 and was expanded in 2018. Chiesi received exclusive rights to commercialize for all markets. Protalix manufactures the drug substance for commercial purposes and post-approval clinical studies. The partnership includes collaboration on clinical development and regulatory approvals, including a $25M milestone payment to Protalix for EC approval of E4W dosing regimen.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2009-11-01
Description

Pfizer is the global partner for commercialization of Elelyso (taliglucerase alfa) for Gaucher disease, excluding Brazil. The collaboration was initiated in November 2009 and restated in October 2015. Under the arrangement, Pfizer received exclusive rights to commercialize taliglucerase alfa for all markets outside Brazil. Protalix manufactures the Elelyso drug substance for commercial purposes. Both companies collaborate in clinical development and regulatory process.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Fiocruz, an arm of the Brazilian Ministry of Health, is the partner for commercialization of alfataliglicerase (Elelyso) in Brazil. Protalix sells the product to Fiocruz at negotiated prices.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Amicus commercializes Galafold (migalastat) for Fabry disease and is developing AT-GAA for Pompe disease, making it a direct therapeutic-area competitor to Protalix's Elfabrio in Fabry and a peer in the rare-disease enzyme replacement / small-molecule chaperone space.

TypeDirect peer
Description

BioMarin is a rare-disease specialist with multiple enzyme replacement and biologic therapies (e.g., Naglazyme, Vimizim, Aldurazyme). It shares Protalix's focus on enzyme-based therapeutics for lysosomal storage and rare metabolic disorders.

TypeDirect peer
Description

Ultragenyx develops biologics and enzyme replacement therapies for rare genetic diseases (e.g., Crysvita, Dojolvi). It is a direct comparator in the rare-disease recombinant biologics space targeting similarly small patient populations.

TypeDirect peer
Description

Sobi is a European rare-disease specialist with enzyme replacement therapies (e.g., Eloctate, Alprolix, Gamifant) and direct overlap with Protalix's commercial model of partnering with larger pharma for distribution.

TypeBroad incumbent
Description

Sanofi's Genzyme unit markets Fabrazyme (agalsidase beta) for Fabry disease and Cerezyme (imiglucerase) for Gaucher disease — the dominant incumbents in Protalix's two core approved indications and the primary share-take competition.

TypeBroad incumbent
Description

Takeda acquired Shire and markets Replagal (agalsidase alfa) for Fabry and Vpriv (velaglucerase alfa) for Gaucher, competing head-to-head with Elfabrio and Elelyso in the same enzyme-replacement market segments.

TypeBroad incumbent
Description

Alexion, AstraZeneca's rare-disease unit, commercializes biologics (e.g., Soliris, Strensiq) for ultra-rare conditions. It overlaps with Protalix in rare-disease biologic commercialization infrastructure and orphan-drug commercial strategy.

TypeBroad incumbent
Description

Amgen's acquisition of Horizon Therapeutics added rare-disease and inflammation assets (e.g., Tepezza, Krystexxa for refractory gout). Krystexxa is a direct competitor to PRX-115 in uncontrolled/refractory gout.

TypeEmerging player
Description

iBio uses a plant-based protein expression platform (FastPharming) similar in concept to Protalix's ProCellEx. It represents the closest emerging technology peer for plant-cell biomanufacturing capability.

TypeBroad incumbent
Description

Regeneron is a large-cap biopharmaceutical company with deep recombinant-protein manufacturing capabilities (VelociSuite) and rare-disease exposure. While not a direct competitor in Protalix's indications, it represents a comparable recombinant-protein platform company at much larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protalix BioTherapeutics

Biopharmaceuticalsprotalix.com

Protalix BioTherapeutics is an Israel-based, publicly traded biopharmaceutical company that develops and manufactures recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression platform, commercializing FDA-approved enzyme replacement therapies Elelyso (Gaucher disease) and Elfabrio (Fabry disease) via partners Pfizer, Chiesi, and Fiocruz.

What Protalix BioTherapeutics does

Protalix BioTherapeutics, Inc. is a publicly traded biopharmaceutical company (NYSE American: PLX) founded in 1994 and headquartered in Carmiel, Israel, that develops and manufactures recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression platform. The company has commercialized two FDA-approved enzyme replacement therapies produced via genetically engineered plant cell suspension cultures in disposable polyethylene bioreactors: Elelyso (taliglucerase alfa) for Type 1 Gaucher disease, approved in 2012 as the first plant cell-expressed protein therapeutic approved by the FDA; and Elfabrio (pegunigalsidase alfa) for adult Fabry disease, approved by the FDA in 2023. Protalix's clinical pipeline includes PRX-115, a PEGylated recombinant uricase in Phase 2 for uncontrolled gout, and PRX-119, a PEGylated DNase I in preclinical research for NETs-related diseases.

The company operates a capital-light, partnership-driven commercialization model. All marketed products are sold through strategic channel partners rather than direct sales infrastructure: Pfizer holds global rights to Elelyso (excluding Brazil, where Fiocruz distributes), and Chiesi Global Rare Diseases holds global rights to Elfabrio. Revenue streams consist of product supply/manufacturing payments, royalties, and regulatory and commercial milestone payments from these partners, supplemented by recent milestone income (e.g., a $25M payment from Chiesi in Q1 2026 tied to European Commission approval of Elfabrio's every-four-weeks dosing regimen). FY2026 revenue is guided to $78-83M with $51.1M of cash as of March 31, 2026. End customers are patients with rare genetic lysosomal storage disorders and (in the pipeline) broader populations with gout and NETs-related diseases; the company is actively seeking additional collaborations to expand its pipeline beyond enzyme replacement therapy into oligonucleotide-based therapeutics for rare renal indications through a December 2025 agreement with Secarna Pharmaceuticals.

Protalix BioTherapeutics firmographics

Firmographics
Name
Protalix BioTherapeutics
Legal name
Protalix BioTherapeutics Inc.
Website
https://protalix.com
Company type
Public
Founded year
1994
Operating status
Operating
Headcount range
101–250 employees
Short description
Protalix BioTherapeutics is an Israel-based, publicly traded biopharmaceutical company that develops and manufactures recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression platform, commercializing FDA-approved enzyme replacement therapies Elelyso (Gaucher disease) and Elfabrio (Fabry disease) via partners Pfizer, Chiesi, and Fiocruz.
Ownership category
akta.pro rank

Protalix BioTherapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Recombinant protein production
  • Enzyme replacement therapy
  • Plant cell expression
  • Biopharmaceutical manufacturing
  • Rare disease therapeutics

Where Protalix BioTherapeutics is headquartered

Location

Headquarters

HQ city
Carmiel
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Protalix BioTherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Product Sales (Elelyso & Elfabrio): Revenue from product sales to commercialization partners including Pfizer (Elelyso) and Chiesi (Elfabrio), as well as Fiocruz in Brazil. Products are approved in multiple markets including US, EU, Brazil, Israel and others.
  2. Milestone Payments: One-time regulatory milestone payments triggered by approvals. Q1 2026 included $25 million milestone from Chiesi following European Commission approval of Elfabrio E4W dosing regimen.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Protalix BioTherapeutics product offering

Product offering

Core offering

Protalix BioTherapeutics develops and manufactures recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company has commercialized two FDA-approved enzyme replacement therapies—Elelyso (taliglucerase alfa) for Type I Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease—through strategic partnerships with Pfizer and Chiesi Global Rare Diseases.

Product overview

Protalix BioTherapeutics is a biopharmaceutical company that has developed two FDA-approved enzyme replacement therapies: Elelyso for type I Gaucher disease and Elfabrio for Fabry disease, both produced through the proprietary ProCellEx plant cell-based expression platform. The company is advancing its clinical pipeline with PRX-115 (PEGylated uricase for uncontrolled gout in Phase 2) and PRX-119 (PEGylated DNase I for NETs-related diseases in research/preclinical stages).

Differentiator

Problem solved

Functional benefit

Brands

  • ProCellEx: Proprietary plant cell-based protein expression platform used to produce recombinant therapeutic proteins
  • Elfabrio
  • Elelyso

Products and services

  • Elfabrio (pegunigalsidase alfa) Elfabrio is an enzyme replacement therapy (ERT) for adult patients with Fabry disease, replacing the deficient alpha-galactosidase-A enzyme through intravenous infusion. It is expressed in plant cell culture with a covalently bound polyethylene glycol polymer linker, commercialized globally by Chiesi Global Rare Diseases.
  • Elelyso (taliglucerase alfa) Elelyso is an enzyme replacement therapy for patients with Type 1 Gaucher disease, replacing the deficient glucocerebrosidase enzyme with a recombinant form of the protein produced through the ProCellEx platform. It was the first plant cell-based recombinant therapeutic protein approved by the FDA, commercialized globally by Pfizer (excluding Brazil) and by Fiocruz in Brazil.
  • PRX-115 PRX-115 is a recombinant PEGylated uricase enzyme in development for the potential treatment of uncontrolled gout. The uricase enzyme converts uric acid to allantoin, designed to lower uric acid levels with low immunogenicity and increased half-life.
  • PRX-119 PRX-119 is a PEGylated Deoxyribonuclease (DNase) I enzyme in development for NETs-related diseases, designed to degrade circulating NETs-related cell-free DNA levels and decrease NET-mediated pathology.
  • ProCellEx Plant Cell-Based Protein Expression Platform ProCellEx is Protalix's proprietary plant cell-based expression platform for producing and manufacturing recombinant therapeutic proteins, offering an alternative to mammalian cell-based production with production, regulatory, and cost benefits. Protalix actively offers the platform for collaborations and co-development of new rare disease therapeutics with high unmet medical need.

Quantifiable outcome

  • Elfabrio approved in US, EU, Great Britain, Switzerland, Israel
  • +3 more outcomes

Companies that use Protalix BioTherapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Protalix BioTherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Protalix BioTherapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Secarna PharmaceuticalsminorStrategic or Co-development Partner · 17 December 2025Collaboration and option agreement to develop oligonucleotide therapies for rare renal indications. Leverages Protalix's expertise in rare diseases and Secarna's AI platform. Joint research with Protalix obtaining exclusive option to license active compounds for clinical development. Companies aim to advance therapies from preclinical stages through clinical trials and potential commercialization.
  • Chiesi Global Rare DiseasescoreChannel Partner/ Reseller/ Distributor · 1 January 2017Chiesi Global Rare Diseases (business unit of Chiesi Group) is the global partner for commercialization of Elfabrio (pegunigalsidase alfa) for Fabry disease. Collaboration began in 2017 and was expanded in 2018. Chiesi received exclusive rights to commercialize for all markets. Protalix manufactures the drug substance for commercial purposes and post-approval clinical studies. The partnership includes collaboration on clinical development and regulatory approvals, including a $25M milestone payment to Protalix for EC approval of E4W dosing regimen.
  • Pfizer Inc.coreChannel Partner/ Reseller/ Distributor · 1 November 2009Pfizer is the global partner for commercialization of Elelyso (taliglucerase alfa) for Gaucher disease, excluding Brazil. The collaboration was initiated in November 2009 and restated in October 2015. Under the arrangement, Pfizer received exclusive rights to commercialize taliglucerase alfa for all markets outside Brazil. Protalix manufactures the Elelyso drug substance for commercial purposes. Both companies collaborate in clinical development and regulatory process.
  • Fundação Oswaldo Cruz (Fiocruz)coreChannel Partner/ Reseller/ DistributorFiocruz, an arm of the Brazilian Ministry of Health, is the partner for commercialization of alfataliglicerase (Elelyso) in Brazil. Protalix sells the product to Fiocruz at negotiated prices.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Protalix BioTherapeutics competitors and assessment

Company assessment

Direct peers

  • Amicus Therapeutics: Amicus commercializes Galafold (migalastat) for Fabry disease and is developing AT-GAA for Pompe disease, making it a direct therapeutic-area competitor to Protalix's Elfabrio in Fabry and a peer in the rare-disease enzyme replacement / small-molecule chaperone space.
  • BioMarin Pharmaceutical: BioMarin is a rare-disease specialist with multiple enzyme replacement and biologic therapies (e.g., Naglazyme, Vimizim, Aldurazyme). It shares Protalix's focus on enzyme-based therapeutics for lysosomal storage and rare metabolic disorders.
  • Ultragenyx Pharmaceutical: Ultragenyx develops biologics and enzyme replacement therapies for rare genetic diseases (e.g., Crysvita, Dojolvi). It is a direct comparator in the rare-disease recombinant biologics space targeting similarly small patient populations.
  • Swedish Orphan Biovitrum (Sobi): Sobi is a European rare-disease specialist with enzyme replacement therapies (e.g., Eloctate, Alprolix, Gamifant) and direct overlap with Protalix's commercial model of partnering with larger pharma for distribution.

Broad incumbents

  • Sanofi (Genzyme): Sanofi's Genzyme unit markets Fabrazyme (agalsidase beta) for Fabry disease and Cerezyme (imiglucerase) for Gaucher disease — the dominant incumbents in Protalix's two core approved indications and the primary share-take competition.
  • Takeda Pharmaceutical (Shire): Takeda acquired Shire and markets Replagal (agalsidase alfa) for Fabry and Vpriv (velaglucerase alfa) for Gaucher, competing head-to-head with Elfabrio and Elelyso in the same enzyme-replacement market segments.
  • AstraZeneca (Alexion): Alexion, AstraZeneca's rare-disease unit, commercializes biologics (e.g., Soliris, Strensiq) for ultra-rare conditions. It overlaps with Protalix in rare-disease biologic commercialization infrastructure and orphan-drug commercial strategy.
  • Amgen: Amgen's acquisition of Horizon Therapeutics added rare-disease and inflammation assets (e.g., Tepezza, Krystexxa for refractory gout). Krystexxa is a direct competitor to PRX-115 in uncontrolled/refractory gout.
  • Regeneron Pharmaceuticals: Regeneron is a large-cap biopharmaceutical company with deep recombinant-protein manufacturing capabilities (VelociSuite) and rare-disease exposure. While not a direct competitor in Protalix's indications, it represents a comparable recombinant-protein platform company at much larger scale.

Emerging players

  • iBio: iBio uses a plant-based protein expression platform (FastPharming) similar in concept to Protalix's ProCellEx. It represents the closest emerging technology peer for plant-cell biomanufacturing capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Protalix BioTherapeutics social profiles

Digital presence

Protalix BioTherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protalix BioTherapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Protalix BioTherapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protalix BioTherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protalix BioTherapeutics

What does Protalix BioTherapeutics do?

Protalix BioTherapeutics develops and manufactures recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company has commercialized two FDA-approved enzyme replacement therapies—Elelyso (taliglucerase alfa) for Type I Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease—through strategic partnerships with Pfizer and Chiesi Global Rare Diseases.

Is Protalix BioTherapeutics a public or private company?

Protalix BioTherapeutics is a public company. It is classified as public and is currently operating.

When was Protalix BioTherapeutics founded?

Protalix BioTherapeutics was founded in 1994. It employs 101 to 250 people.

Where is Protalix BioTherapeutics based?

Protalix BioTherapeutics is headquartered in Carmiel, Israel, in the Middle East region.

How does Protalix BioTherapeutics make money?

Two revenue lines are on record. Product Sales (Elelyso & Elfabrio) is the primary driver. The others are milestone Payments.

Who are Protalix BioTherapeutics's main competitors?

Direct peers on record are Amicus Therapeutics, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Swedish Orphan Biovitrum (Sobi). Broad incumbents are Sanofi (Genzyme), Takeda Pharmaceutical (Shire), AstraZeneca (Alexion), Amgen and Regeneron Pharmaceuticals. iBio is listed as an emerging player.

Does Protalix BioTherapeutics have an API?

No public API is recorded for Protalix BioTherapeutics.

What industry is Protalix BioTherapeutics in?

Protalix BioTherapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAAAK, Therapeutic Enzymes & Enzyme Replacement Therapies (ERT). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaProtalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call TranscriptProtalix BioTherapeutics reported Q3 2026 revenue of $75.6 million, reflecting continued progress and a growing financial position. The company's CEO, Dror Bashan, stated this supports execution of its strategy and advancement of key initiatives.BenzingaProtalix BioTherapeutics Q3 2026 Earnings Call Transcript - Protalix BioTherapeutics (AMEX:PLX)Protalix BioTherapeutics reported Q3 2026 revenues of $21.9 million, up from $17.9 million a year earlier, with net income of $4 million. The company ended the quarter with $48.5 million in cash and no debt. Management expects continued growth from Elfabrio and PRX115, with phase 2 results expected in the second half of next year.Business & FinancialFabry Disease Pipeline 2026: How New Mechanisms And Late-Stage Trials Are Reshaping The Treatment Paradigm Chiesi And Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix BioDelveInsight's Fabry Disease Pipeline 2026 report outlines emerging therapies and late-stage trials. Key updates include PTC Therapeutics' rolling BLA for ST-920 in Q4 2026 and Idorsia's FAB-KLEAR Phase III trial for lucerastat. The report also covers other candidates like ELFABRIO and Venglustat.The future of tradingProtalix BioTherapeutics to Report Third-Quarter Financial ResultsProtalix BioTherapeutics will report its third-quarter 2026 financial results on November 10, 2026, with a business update. Management will host a conference call and webcast on November 10 at 8 a.m. ET to discuss the results and corporate developments.American Banking and Market NewsContrasting Protalix BioTherapeutics (NYSE:PLX) & 4D Molecular Therapeutics (NASDAQ:FDMT)Protalix BioTherapeutics and 4D Molecular Therapeutics are compared on valuation, profitability, and analyst ratings. Protalix has higher earnings and a stronger consensus rating, with a 363% upside target versus 4D's 154%. Analysts favor Protalix as the more favorable investment.American Banking and Market NewsFinancial Survey: Mereo BioPharma Group (NASDAQ:MREO) vs. Protalix BioTherapeutics (NYSE:PLX)Mereo BioPharma Group and Protalix BioTherapeutics are compared on analyst ratings, institutional ownership, and profitability. Mereo has a higher consensus target price and more institutional ownership, while Protalix shows higher revenue and earnings. Analysts favor Mereo due to its higher potential upside.Seeking AlphaProtalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptProtalix BioTherapeutics CFO Gilad Mamlok presented at Morgan Stanley's 24th Annual Global Healthcare Conference, outlining the company's rare disease focus. The company holds two licensed products: Elelyso (Gaucher disease) licensed to Pfizer and Elfabrio (Fabry) to Chiesi, with Brazil revenue of $11 million in 2025.American Banking and Market NewsResearch Analysts Set Expectations for PLX FY2027 EarningsHC Wainwright reduced its FY2027 earnings estimate for Protalix BioTherapeutics to $0.11 per share, down from $0.12, and maintains a Buy rating with a $12 price target. The consensus full-year estimate is $0.01, and the company's stock opened at $2.64.AInvestProtalix Biotherapeutics’ Elfabrio Sales Volatility and PRX-115 Market Projections Clash in Q2 2026 Earnings CallProtalix Biotherapeutics reported Q2 2026 revenue of $19.9 million, up 26% year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company holds $40.7 million in cash with no debt, and R&D costs fell 26% to $4.4 million. Management confirmed full-year 2026 guidance alignment, with PRX-115 phase III data expected in H2 2027.The Motley FoolProtalix (PLX) Q2 2026 Earnings Call TranscriptProtalix BioTherapeutics reported a significant increase in Q2 2026 revenue to $19.9 million, driven by global sales of Elfabrio through partner Chiesi and a $25 million milestone payment. The company maintains its full-year 2026 revenue guidance of $78–$83 million and highlighted regulatory approvals for Elfabrio in South Korea and a patent extension in the United States. Additionally, Protalix provided updates on its clinical pipeline, noting that enrollment for the PRX-115 Phase 2 study is expected to conclude within five months.